PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

This research study is currently not recruiting patients.

See other Pinealoma Research Studies

PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Study Overview

The overall goal of this study is to compare the effects, good and/or bad, of the chemotherapy drugs carboplatin and isotretinoin on subjects with high risk medulloblastoma and to find out if one or both are better than standard therapy alone.

Study Description

The purpose of this study is to determine whether carboplatin radiosensitization increases long term event-free survival for high risk medulloblastoma/primitive neuroectodermal tumor (PNET) patients and to determine whether isotretinoin increases long term event-free survival for high risk medulloblastoma/PNET patients.

Additional Information:

Participants will not be paid for their participation.

Research Study Identifier: TX481

ClinicalTrials.gov Identifier: NCT1106005984 (0707-01)

Principal Investigator: Kamnesh Pradhan, MD

Not Recruiting

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

Last Name

First name is mandatory

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Last Updated: Jan 24, 2019

Recruitment Status: Closed